冲动控制和与多巴胺激动剂血清度的相关性在患有帕金森病的人群中
Sara C Staubo1,2,3, Ole Martin Fuskevåg4,5,6, Mathias Toft1,2
1Department of Neurology, Oslo University Hospital, Rikshospitalet, Nydalen, PO Box 4950, N-0424, Oslo, Norway.
Journal of neurology
|January 15, 2025
概括
帕金森病 (PD) 患者的冲动控制问题与罗皮尼罗尔暴露和剂量有关,但与普拉米索尔无关. 减少罗皮尼罗尔剂量可能有所帮助,而普拉米佩克索尔可能需要停止使用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 运动障碍 运动障碍
背景情况:
- 多巴胺激动剂经常用于治疗帕金森病 (PD).
- 冲动控制受损,包括强迫行为,是一些PD患者在服用这些药物的已知的副作用.
研究的目的:
- 为了研究使用罗皮尼罗尔或普拉米佩克索尔的PD患者的血清度和冲动控制之间的关系.
- 为了确定药物暴露 (AUC) 或剂量是否与帕金森病评分尺度 (QUIP-RS) 中冲动-强迫性障碍问卷得分相关.
主要方法:
- 一项治疗药物监测研究对100名PD患者进行,这些患者接受延长释放罗宾或普拉米.
- 为了测量血清度和计算曲线下的24小时面积 (AUC),收集了三份血液样本.
- 使用帕金森病评分尺度 (QUIP-RS) 验证的冲动-强迫性障碍问卷来评估冲动控制.
主要成果:
- 罗皮尼罗尔的总药物暴露 (AUC) 与 QUIP-RS 评分存在微弱但显著的相关性.
- 在血清中pramipexole度和QUIP-RS得分之间没有发现相关性.
- 对于罗皮尼罗尔,激动剂剂量和多巴胺治疗总持续时间与QUIP-RS相关. 在两组药物中,任何与QUIP-RS相关的多巴胺治疗的持续时间.
结论:
- 患有PD患者的冲动控制障碍与罗皮尼罗尔的总药物暴露和剂量有关,但与普拉米佩克索尔无关.
- 这些发现表明,降低罗皮尼罗尔剂量可能是管理冲动控制问题的可行策略.
- 在PD患者经历这些行为副作用时,可能需要停止使用pramipexole.
更多相关视频
11:26Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
Published on: September 21, 2017
12.4K
06:45Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
2.6K
相关概念视频
Parkinson's Disease: Treatment
206
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
206
Parkinson's Disease: Overview
463
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
463
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Drug Concentration Versus Time Correlation
606
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
606
